BACKGROUND: Distinguishing hereditary non-polyposis colorectal cancer (HNPCC) from non-hereditary colorectal cancer (CRC) can increase the life expectancy of HNPCC patients and their close relatives. AIM: To determine the effectiveness, efficiency, and feasibility of a new strategy for the detection of HNPCC, using simple criteria for microsatellite instability (MSI) analysis of newly detected tumours that can be applied by pathologists. Criteria for MSI analysis are: (1) CRC before age 50 years; (2) second CRC; (3) CRC and HNPCC associated cancer; or (4) adenoma before age 40 years. METHODS: The efficacy and cost effectiveness of the new strategy was evaluated against current practice. Decision analytic models were constructed to estimate the number of extra HNPCC mutation carriers and the costs of this strategy. The incremental costs and gain in life expectancy for a HNPCC mutation carrier were evaluated by Markov modelling. Feasibility was explored in five hospitals. RESULTS: Using the new strategy, 2.2 times more HNPCC patients can be identified among a CRC population compared with current practice. This new strategy was found to be cost effective with an expected cost effectiveness ratio of 3801 per life year gained. When including the group of siblings and children, the cost effectiveness ratio became 2184 per life year gained. Sensitivity analysis showed these findings to be robust. CONCLUSIONS: MSI testing in a selection of newly diagnosed CRC patients was shown to be cost effective and a feasible method to identify patients at risk for HNPCC who are not recognised by family history.
BACKGROUND: Distinguishing hereditary non-polyposis colorectal cancer (HNPCC) from non-hereditary colorectal cancer (CRC) can increase the life expectancy of HNPCC patients and their close relatives. AIM: To determine the effectiveness, efficiency, and feasibility of a new strategy for the detection of HNPCC, using simple criteria for microsatellite instability (MSI) analysis of newly detected tumours that can be applied by pathologists. Criteria for MSI analysis are: (1) CRC before age 50 years; (2) second CRC; (3) CRC and HNPCC associated cancer; or (4) adenoma before age 40 years. METHODS: The efficacy and cost effectiveness of the new strategy was evaluated against current practice. Decision analytic models were constructed to estimate the number of extra HNPCC mutation carriers and the costs of this strategy. The incremental costs and gain in life expectancy for a HNPCC mutation carrier were evaluated by Markov modelling. Feasibility was explored in five hospitals. RESULTS: Using the new strategy, 2.2 times more HNPCC patients can be identified among a CRC population compared with current practice. This new strategy was found to be cost effective with an expected cost effectiveness ratio of 3801 per life year gained. When including the group of siblings and children, the cost effectiveness ratio became 2184 per life year gained. Sensitivity analysis showed these findings to be robust. CONCLUSIONS: MSI testing in a selection of newly diagnosed CRC patients was shown to be cost effective and a feasible method to identify patients at risk for HNPCC who are not recognised by family history.
Authors: H F Vasen; M van Ballegooijen; E Buskens; J K Kleibeuker; B G Taal; G Griffioen; F M Nagengast; F H Menko; P Meera Khan Journal: Cancer Date: 1998-05-01 Impact factor: 6.860
Authors: L A Aaltonen; R Salovaara; P Kristo; F Canzian; A Hemminki; P Peltomäki; R B Chadwick; H Kääriäinen; M Eskelinen; H Järvinen; J P Mecklin; A de la Chapelle Journal: N Engl J Med Date: 1998-05-21 Impact factor: 91.245
Authors: B Liu; R Parsons; N Papadopoulos; N C Nicolaides; H T Lynch; P Watson; J R Jass; M Dunlop; A Wyllie; P Peltomäki; A de la Chapelle; S R Hamilton; B Vogelstein; K W Kinzler Journal: Nat Med Date: 1996-02 Impact factor: 53.440
Authors: Aparna Mukherjee; Thomas J McGarrity; Francesca Ruggiero; Walter Koltun; Kevin McKenna; Lisa Poritz; Maria J Baker Journal: Hered Cancer Clin Pract Date: 2010-11-22 Impact factor: 2.857
Authors: Frauke Becker; Carla G van El; Dolores Ibarreta; Eleni Zika; Stuart Hogarth; Pascal Borry; Anne Cambon-Thomsen; Jean Jacques Cassiman; Gerry Evers-Kiebooms; Shirley Hodgson; A Cécile J W Janssens; Helena Kaariainen; Michael Krawczak; Ulf Kristoffersson; Jan Lubinski; Christine Patch; Victor B Penchaszadeh; Andrew Read; Wolf Rogowski; Jorge Sequeiros; Lisbeth Tranebjaerg; Irene M van Langen; Helen Wallace; Ron Zimmern; Jörg Schmidtke; Martina C Cornel Journal: Eur J Hum Genet Date: 2011-04 Impact factor: 4.246
Authors: Paul G van Putten; Margot G F van Lier; Mariska Hage; Katharina Biermann; Reinier H van Rijssel; Pieter J Westenend; Hans Morreau; Ewout W Steyerberg; Winand N M Dinjens; Ernst J Kuipers; Monique E van Leerdam; J Han van Krieken Journal: Fam Cancer Date: 2014-09 Impact factor: 2.375
Authors: Uri Ladabaum; Grace Wang; Jonathan Terdiman; Amie Blanco; Miriam Kuppermann; C Richard Boland; James Ford; Elena Elkin; Kathryn A Phillips Journal: Ann Intern Med Date: 2011-07-19 Impact factor: 25.391
Authors: L I Overbeek; R P Hermens; J H van Krieken; E M Adang; M Casparie; F M Nagengast; M J Ligtenberg; N Hoogerbrugge Journal: Virchows Arch Date: 2010-04-09 Impact factor: 4.064
Authors: Fay Kastrinos; John I Allen; David H Stockwell; Elena M Stoffel; Earl F Cook; Muthoka L Mutinga; Judith Balmaña; Sapna Syngal Journal: Am J Gastroenterol Date: 2009-04-28 Impact factor: 10.864
Authors: Karin M Landsbergen; Judith B Prins; Han G Brunner; Floris W Kraaimaat; Nicoline Hoogerbrugge Journal: Fam Cancer Date: 2009-03-28 Impact factor: 2.375